Project Grant R44HL170834
Award Date
7/15/24
Completion Date
7/14/26
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Eydis Bio, Inc. (MWWCM7JMBCF1)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,999 to Altay Therapeutics, Inc. to develop a STAT3 inhibitor for treating lung fibrosis associated with systemic sclerosis (SSc-ILD). The project aims to characterize the lead STAT3 inhibitor compound, evaluate its anti-fibrotic efficacy in SSc-ILD patient tissues, and demonstrate its therapeutic and prophylactic effects in an animal...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the assessment of a peptide-based therapy for treating lung fibrosis, a common and serious condition associated with systemic sclerosis. The $389,754 award to Thendor Therapeutics LLC will fund in vivo studies evaluating the therapeutic potential of the peptide in a murine model of lung fibrosis....
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $548,708 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oncoarendi Therapeutics LLC. The grant's objective is to develop a novel, disease-modifying oral medication for idiopathic pulmonary fibrosis (IPF) that targets the myocardin-related transcription factor (MRTF) pathway. The key goals of this Phase I project are to optimize a lead compound...
This is a Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The primary grant recipient is the Sanford Burnham Prebys Medical Discovery Institute (SBP), located in La Jolla, CA. The goal of this R61/R33 phased grant is to further characterize and optimize novel small molecule inhibitors that selectively target the YAP/TAZ transcription co-factors in lung fibroblasts, with the aim of...
This federal Project Grant award in the amount of $542,402.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports a research project that aims to identify small molecules capable of reversing profibrotic gene signatures associated with idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with high mortality. The key objectives are: 1) in silico discovery of drug candidates that...
This $286,739 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Fibronox, L.L.C., a woman-owned small business. The project aims to assess the clinical translatability of inhaled Nrf2 activator therapy for idiopathic pulmonary fibrosis (IPF), a devastating age-related fibrotic disease with limited treatment options. Specifically, the work will evaluate the efficacy of three FDA-approved...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The total funding amount is $356,250.00, awarded on September 15, 2024, with a planned completion date of February 28, 2025. The project is being conducted by Vasarya Therapeutics, Inc., a for-profit, woman-owned...
This $1,644,550 Cooperative Agreement awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports comprehensive research to understand how interactions between epithelial, mesenchymal, and matrix compartments drive the progression of fibrosis in interstitial lung diseases (ILD). The research aims to: 1) use spatial transcriptomics to profile airway epithelium and underlying fibroblasts in ILD samples, 2a) employ...
This Project Grant award, valued at $1,909,362, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The goal of the funded project is to perform a side-by-side evaluation of the top three most promising NOX4 inhibitor drug candidates for the treatment of pulmonary fibrosis, with a focus on validating selectivity, assessing mode of action, and determining the therapeutic index and maximum tolerated...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,748 to Mechanobiologix LLC to develop a stiffness-based drug discovery platform for idiopathic pulmonary fibrosis (IPF). The key products and services to be delivered include: Integrating micro- and macro-scale stiffness measurements in human precision-cut lung slices (HPCLS) with traditional IPF research endpoints to...